Clinical Trial Update: Clinical, Neurocognitive, and Emotional Effects of Psilocybin in Depressed Patients - Proof of Concept [Phase 2]

View source ↗

Summary

A Phase 2 proof-of-concept study evaluating the clinical, neurocognitive, and emotional effects of psilocybin in patients with major depressive disorder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• Psilocybin (psilocybin)

Snippet

Sponsor: University of Zurich | Conditions: Depressive Disorder, Major | Phase 2 | Status: COMPLETED